Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.

Masaomi IyoJun IshigookaMasatoshi NakamuraReiko SakaguchiKeisuke OkamotoYongcai MaoJoyce TsaiAlison FitzgeraldKentaro TakaiTeruhiko Higuchi

Published in: Neuropsychiatric disease and treatment (2021)

Treatment with lurasidone 40 or 80 mg once daily (flexibly dosed) continued to be well tolerated with patients demonstrating further improvement in symptoms over the course of a 12-week open-label extension study in patients with schizophrenia.

Keyphrases

open label
end stage renal disease
clinical trial
randomized controlled trial
chronic kidney disease
ejection fraction
newly diagnosed
squamous cell carcinoma
peritoneal dialysis
physical activity
radiation therapy
depressive symptoms
phase iii
patient reported outcomes
combination therapy